Friday, 24 March 2017

EMA panel backs Novo Nordisk's hemophilia B drug

(Reuters) - A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's hemophilia B drug.


No comments:

Post a Comment